Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies, including a menin inhibitor for R/R acute leukemia and a monoclonal antibody for chronic graft-versus-host disease
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies, including a menin inhibitor for R/R acute leukemia and a monoclonal antibody for chronic graft-versus-host disease.
The top three firms on F4's Biotech & Life Sciences investor list.